Alexandra Santana Sørensen
Plus aucun poste en cours
Provenance du réseau au premier degré de Alexandra Santana Sørensen
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Food: Specialty/Candy | 14 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Alexandra Santana Sørensen via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Banque Lombard Odier & Cie SA (Investment Management)
Banque Lombard Odier & Cie SA (Investment Management) Investment ManagersFinance Banque Lombard Odier & Cie SA (Investment Management) (Lombard Odier-IM) is the investment management division of Banque Lombard Odier & Cie, a subsidiary of Compagnie Lombard Odier SCmA in Switzerland. The firm was founded in 2002 when Lombard Odier & Cie and Darier Hentsch & Cie. merged. They are headquartered in Geneva with branches and representative offices throughout Switzerland, Europe, the Americas, Asia Pacific and the Middle East. Lombard Odier-IM provides private banking and asset management services to institutions, family-owned businesses and high-net worth individuals. They also provide a range of support services for independent intermediaries. | Investment Managers | Corporate Officer/Principal | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
OMEROS CORPORATION | Pharmaceuticals: Major | Director/Board Member | |
Nura, Inc.
Nura, Inc. Pharmaceuticals: MajorHealth Technology Nura, Inc. discovers and develops pharmaceutical products. It offers products for the treatment of neurodegenerative diseases such as Parkinson's & Alzheimer's diseases and behavioural disorders such as depression, anxiety, schizophrenia, obesity, and addiction. The company was founded in August 2003 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member | |
Gyros AB
Gyros AB Medical SpecialtiesHealth Technology Gyros AB engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays. Its Gyrolab xP miniaturizes, integrates, and automates analysis of samples in parallel. The firm's technology delivers immunoassay data through automated control of centrifugal and capillary forces to steer liquid flow in proprietary nanoliter-scale microfluidic structures.The company offers Gyrolab microlaboratory, in the form of a compact disk, can process samples at nanoliter scale, controlled by Gyrolab Workstation. Gyros was founded in 2000 and is headquartered in Uppsala, Sweden. | Medical Specialties | Director/Board Member Director/Board Member | |
Burrill LLC
Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
ALK-ABELLÓ A/S | Biotechnology | Director/Board Member | |
University of Cambridge | College/University | Director/Board Member | |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor | |
Ferrosan ApS
Ferrosan ApS Pharmaceuticals: OtherHealth Technology Ferrosan ApS manufactures and sells pharmaceutical products. Its products include herbal medicine, natural remedies, food supplements, and medical devices. The company was founded by Niels Jacob Herman Weitzmann in 1920 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Other | Sales & Marketing | |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member | |
University of Copenhagen | College/University | Doctorate Degree Graduate Degree Graduate Degree | |
Ruprecht-Karls-Universität Heidelberg | College/University | Director/Board Member | |
University of Geneva | College/University | Masters Business Admin | |
Aravis AG
Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Investment Managers | Founder | |
SYMETIS SA | Biotechnology | Director/Board Member Director/Board Member | |
MerLion Pharmaceuticals Pte Ltd.
MerLion Pharmaceuticals Pte Ltd. Miscellaneous Commercial ServicesCommercial Services MerLion Pharmaceuticals Pte Ltd. provides drug discovery and development services. It focuses on developing its lead antibacterial candidate, finafloxacin, through early and mid-stage clinical trials. The company was founded in 2002 and is headquartered in Singapore. | Miscellaneous Commercial Services | Chairman | |
S*BIO Pte Ltd.
S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Pharmaceuticals: Major | Director/Board Member | |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal Chairman Director of Finance/CFO Founder Corporate Officer/Principal Chief Tech/Sci/R&D Officer Founder | |
OpGen A/S
OpGen A/S Medical SpecialtiesHealth Technology Part of OpGen, Inc., OpGen A/S is a Danish company that develops and markets molecular-based in vitro diagnostic tests. The company is based in Vedbaek, Denmark. | Medical Specialties | Director/Board Member | |
Sensimed SA
Sensimed SA Medical SpecialtiesHealth Technology Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Chairman | |
Medical Vision AB
Medical Vision AB Medical SpecialtiesHealth Technology Medical Vision AB provides medical devices used during endoscopic surgeries. It develops, manufactures and markets medical devices within the field of Arthroscopic surgery. The firm's core product is called Double Pump, and is used to flush fluids through the joint with a controlled pressure and flow to increase visualization during the procedure. The company was founded by Anders Gunnar Möllstam in 2003 and is headquartered in Nacka, Sweden. | Medical Specialties | Director/Board Member | |
Fondation Fournier Majoie pour l'Innovation EtUtPub
Fondation Fournier Majoie pour l'Innovation EtUtPub Miscellaneous Commercial ServicesCommercial Services Fondation Fournier Majoie pour l'Innovation EtUtPub is a social services provider based in Brussels, Belgium. The Belgian company provides social services. | Miscellaneous Commercial Services | Director/Board Member | |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Chairman | |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman | |
iSD Immunotech ApS
iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Biotechnology | Chief Executive Officer | |
Celltech Pharmaceuticals, Inc. | Chief Executive Officer | ||
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman | |
Meta-IQ | Chief Executive Officer | ||
SLS Invest AB | Investment Managers | Chief Executive Officer | |
UCB Nordic AS | Director/Board Member |
Statistiques
Internationale
Danemark | 18 |
Suisse | 13 |
Etats-Unis | 7 |
Allemagne | 7 |
Suède | 5 |
Sectorielle
Health Technology | 29 |
Commercial Services | 9 |
Finance | 8 |
Consumer Services | 5 |
Opérationnelle
Director/Board Member | 104 |
Corporate Officer/Principal | 43 |
Chairman | 31 |
Founder | 18 |
Chief Executive Officer | 16 |
Relations les plus connectées
- Bourse
- Insiders
- Alexandra Santana Sørensen
- Connexions Sociétés